Indication Target Mode of Action
Oncology
STING
Agonist
IND enabling
Inflammation
STING
Antagonist
Lead Generation stage
Oncology
ACSS2
Inhibitor
Candidate Selection stage
Oncology
TDO/IDO
Inhibitor
IND enabling stage
Oncology
HPK1
Inhibitor
Lead Generation stage
Lead Generation stage
